Clinically proven treatment for migraine without drugs

Healthcare & Medical

Company Description

Theranica’s drug-free migraine treatment device is based on recent advances in neuroscience. The company’s device, Nerivio®, is a digitally connected wearable arm band that utilizes Theranica’s patented remote electrical neuromodulation technology. Nerivio stimulates the body’s pain receptors in order to relieve acute and chronic migraine pain ‒ easily and safely. Nerivio is FDA approved for acute treatment of migraine and is under FDA review for preventive treatment. To date, Nerivio has been prescribed to over 35,000 patients in the US.

The company was founded by Shimon Eckhouse, a leading Israeli MedTech entrepreneur who has founded more than 20 startups; CEO Alon Ironi, an experienced entrepreneur; COO Ronen Jashek, an international marketing, sales, and business development executive; and VP R&D Slava Barabash, a seasoned wireless communications technologist. The company’s medical and scientific team includes a solid group of PhDs in neuroscience, backed by a medical advisory board which includes the world’s top headache specialists.

The details here are based on information received from, and verified solely by, the company.
Amount Raised : $0
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Research Reports

No reports have been submitted

Become a Reporter